Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06757647 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 2 study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by Seema Bhat.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT06757647: Recruiting Phase 2 study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by Seema Bhat.
NCT06757647 is a Phase 2 study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma that is actively recruiting participants, run by Seema Bhat. The registered enrollment target is 61 participants, above the 43-participant average among 7 other Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06757647, a Phase 2 study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, is actively recruiting participants, sponsored by Seema Bhat.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well acalabrutinib works in treating patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and evaluates how treatment with acalabrutinib affects heart function. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. CLL/SLL patients treated with a different BTK inhibitor called ibrutinib often experience cardiac side effects, leading to discontinuation of life-saving therapy. Treatment with acalabrutinib after discontinuing, or even before starting, treatment with ibrutinib may reverse or prevent cardiac side effects and be an effective treatment option for patients with CLL/SLL.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Aspiration
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- DRUG Acalabrutinib
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2025-05-27 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06757647
The ClinicalTrials.gov registry entry for NCT06757647 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 43-participant average among 7 other Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trials with a reported enrollment target (42% higher). The listed sponsor is Seema Bhat, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06757647 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06757647 about?
NCT06757647 is a clinical study titled "Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma". This phase II trial tests how well acalabrutinib works in treating patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and evaluates how treatment with acalabrutinib affects heart function. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a...
What is the current status of trial NCT06757647?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2025-05-27. Estimated completion is 2027-12-31.
What conditions does trial NCT06757647 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT06757647?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT06757647?
This trial is sponsored by Seema Bhat, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06757647 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
RECRUITING · Phase 2
-
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
RECRUITING · NA
-
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
RECRUITING · NA
-
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.